<DOC>
	<DOCNO>NCT00112489</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give paclitaxel together carboplatin work treat patient persistent recurrent stage III stage IV uterine cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin Treating Patients With Persistent Recurrent Stage III Stage IV Uterine Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity paclitaxel carboplatin patient persistent recurrent stage III IV uterine carcinosarcoma . - Determine nature degree toxicity regimen patient . OUTLINE : This non-randomized , multicenter study . Patients receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : Approximately 14-47 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm uterine carcinosarcoma ( mixed mesodermal tumor ) Stage III IV disease Persistent recurrent disease Documented disease progression Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan At least 1 target lesion Tumors within previously irradiate field consider target lesion unless documented disease progression Ineligible high priority Gynecology Oncology Group ( GOG ) protocol ( i.e. , active GOG phase III protocol patient population ) PATIENT CHARACTERISTICS : Age 18 Performance status GOG 02 Life expectancy Not specify Hematopoietic Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require antibiotic No invasive malignancy within past 5 year except nonmelanoma skin cancer No sensory motor neuropathy &gt; grade 1 PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior cytotoxic chemotherapy uterine sarcoma Endocrine therapy At least 1 week since prior hormonal therapy uterine sarcoma Concurrent hormone replacement therapy allow Radiotherapy See Disease Characteristics Surgery Not specify Other Recovered prior therapy No prior anticancer therapy would preclude study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
</DOC>